It might be prudent to pay attention to the AVEO re-structuring conference call tomorrow AM. They are expected to announce development plans for ficla, a MAB of the HGF/c-Met pathway. Whatever strategy they employ, it'll be interesting to see how they intend to dance with Cabo as an obvious competitor in the c-Met space. They are currently fully enrolled in a P2 in NSCLC comparing gefitinib plus ficla to gefitinib monotherapy. Early results have been favorable, for all the same rationale that supports Cabo.